Top 5 Drug Type | Count |
---|---|
Small molecule drug | 14 |
Synthetic peptide | 2 |
mRNA | 1 |
Recombinant polypeptide | 1 |
Chemical drugs | 1 |
Target |
Mechanism CD73 inhibitors |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism PDL1 inhibitors |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism Bacterial growth inhibitors |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date20 Jul 2024 |
Sponsor / Collaborator |
Start Date16 Oct 2019 |
Sponsor / Collaborator |
Start Date01 Mar 2013 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
isobavachalcone ( DHODH ) | Acute Myeloid Leukemia More | Preclinical |
JNK1 inhibitor(Matrix Biopharmaceutical) ( JNK1 ) | Idiopathic Pulmonary Fibrosis More | Preclinical |
PDL1 inhibitors(East China University of Science & Technology) ( PDL1 ) | Candida Auris Infection More | Preclinical |
PI3K/AKT/GSK3β modulators(East China University of Science & Technology) ( Akt x GSK-3β x PI3Ks ) | Heart Failure More | Preclinical |
βLys50HG50 | MRSA - Methicillin resistant Staphylococcus aureus infection More | Preclinical |